LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Akciju saraksts・Denali Therapeutics Inc

Denali Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

19.47 -3.04

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

19.19

Max

19.74

Galvenie mērījumi
By Trading Economics
Ienākumi	102K -128M
EPS	-0.69
Darbinieki	507
EBITDA	-9.8M -135M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+76.27% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	277M 3.2B
Iepriekšējā atvēršanas cena	22.51
Iepriekšējā slēgšanas cena	19.47

Ziņu noskaņojums

By Acuity

67%

33%

290 / 344 Rangs Healthcare

Denali Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. jūn. 19:20 UTC

Galvenie tirgus virzītāji

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

2026. g. 5. jūn. 21:27 UTC

Peļņas

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

2026. g. 5. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. jūn. 20:20 UTC

Iegādes, apvienošanās, pārņemšana

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

2026. g. 5. jūn. 20:19 UTC

Iegādes, apvienošanās, pārņemšana

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

2026. g. 5. jūn. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 5. jūn. 19:26 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 5. jūn. 19:26 UTC

Tirgus saruna

Hog Futures Tumble to Close Week -- Market Talk

2026. g. 5. jūn. 19:10 UTC

Tirgus saruna

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

2026. g. 5. jūn. 19:03 UTC

Tirgus saruna

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

2026. g. 5. jūn. 18:59 UTC

Tirgus saruna

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

2026. g. 5. jūn. 18:47 UTC

Tirgus saruna

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

2026. g. 5. jūn. 18:34 UTC

Tirgus saruna

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

2026. g. 5. jūn. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

2026. g. 5. jūn. 17:50 UTC

Peļņas

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

2026. g. 5. jūn. 17:27 UTC

Tirgus saruna

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

2026. g. 5. jūn. 16:48 UTC

Iegādes, apvienošanās, pārņemšana

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 5. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 5. jūn. 15:44 UTC

Iegādes, apvienošanās, pārņemšana

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026. g. 5. jūn. 15:26 UTC

Tirgus saruna

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

2026. g. 5. jūn. 15:25 UTC

Peļņas

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

2026. g. 5. jūn. 15:16 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 5. jūn. 15:16 UTC

Tirgus saruna

Zcash Tumbles After Exploit Found -- Market Talk

2026. g. 5. jūn. 15:09 UTC

Tirgus saruna

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

2026. g. 5. jūn. 15:07 UTC

Tirgus saruna

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

2026. g. 5. jūn. 15:05 UTC

Tirgus saruna

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Salīdzinājums

Cenas izmaiņa

Denali Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

76.27% augšup

Prognoze 12 mēnešiem

Vidējais 35.5 USD 76.27%

Augstākais 42 USD

Zemākais 23 USD

Pamatojoties uz 13 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Denali Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

13 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 13 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Denali Therapeutics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

290 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.